Vitrafy Life Sciences Ltd (ASX: VFY) Share Price and News

Ms Munnings has experience as a senior executive at ASX listed health and services companies. While at Virtus Health, Kate created Virtus Ventures, which included successful collaborations between Virtus Health and a range of biotech start ups, to undertake translational research, commercialise technology and obtain innovation grants. Kate is currently Chair of the Digital Health Cooperative Research Centre. Kate has operational experience, including as Chief Operations Officer at Ramsay Health Care (ASX:RHC), and as Chief Executive Operations Officer at Transfield Services (previously ASX:TSE) (now Ventia Services Group Limited). Before moving into operations, Kate was Chief Risk and Legal Officer/Company Secretary for eight years. Kate was previously a partner at Corrs Chambers Westgarth, and Baker McKenzie.

Mr Webber has industry and public markets experience, having spent more than 20 years in corporate finance at Australian stockbrokers, focusing on developing, funding and executing strategies for mid to small cap ASX listed companies (including IPO experience). Vaughan has held and currently holds directorships in private and other public companies. He is chair of the Risk Committee.

Dr Farrell brings over 30 years of leadership experience across the biotechnology, pharmaceutical and medical technology sectors. Most recently, Dr Farrell served as Head of Health Security Systems Australia (a division of DMTC Ltd). Prior to this, he held senior US-based roles as Senior Vice President, Commercial at Certara USA, Inc. His experience spans senior positions at Biota Pharmaceuticals, GBS Venture Partners and Johnson & Johnson Research. Dr Farrell currently serves as a Non-Executive Director of ASX-listed Pro Medicus Limited (ASX: PME) and holds board positions with Ena Respiratory Pty Limited and Axelia Oncology Pty Limited. He is also an Advisory Board Member at Medicines Australia and is a Committee Member on the Walter & Eliza Hall Institute, Medical Research Board Commercialisation Committee. He is also the past Chair of the Medical Countermeasures Products Australia, an unincorporated public-private partnership between Departments of Health and Aged Care, Defence Department, Defence Science and Technology Group, CSIRO, industry and academia.

Dr Jeannette has three decades of executive and board experience, Dr Joughin brings expertise to Vitrafy, particularly in blood and blood-related application areas. Dr Joughin has held senior roles at leading organisations including CSL, Bristol Myers Squibb and Enable Injections. Dr Joughin has held various director roles across biotechnology and medical devices in Australia and internationally, supporting portfolio and ASX listed companies through growth, operations, licensing and business development. She currently serves as a Non-Executive Director of ImmVirX Ltd, Immuron Ltd (IMC.ASX), Argenica Therapeutics (AGN.ASX) and BiVACOR Australia Pty Ltd. She is also a Venture Partner supporting the Healthcare team at OneVentures, one of Australias leading venture capital firms.

Mr Owens is an entrepreneur and co inventor of Vitrafy technology, with experience in intellectual property development. He has played a role in pioneering Vitrafy's technological innovations, product development and enterprise grade software, securing collaboration agreements, grant funding and securing supporting patent protection. Brent is responsible for developing and implementing the strategic vision for Vitrafy, ensuring the alignment of its technology innovations with customer needs, creating commercial opportunities.

-

-

-